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Progressive multifocal leukoencephalopathy is a currently
untreatable infection of the brain. Here, we demonstrate in
2 patients that treatment with interleukin 7, JC polyomavirus
(JCV) capsid protein VP1, and a Toll-like receptor 7 agonist
used as adjuvant, was well tolerated, and showed a very favor-
able safety proﬁle and unexpected efﬁcacy that warrant
further investigation.
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Progressive multifocal leukoencephalopathy (PML) is a life-
threatening opportunistic infection of the brain caused by JC
polyomavirus (JCV) [1] that occurs in various states of immu-
nosuppression. The occurrence of PML in conditions of de-
creased CD4+ T-cell numbers or function with resolution
following their restoration [2] and immunological studies
from brain-inﬁltrating T-cells [3] strongly support the impor-
tance of these immune cells in controlling JCV infection.
JCV-speciﬁc CD8+ cytotoxic T-cells also play an important
role in controlling this infection and have been linked to recov-
ery from PML [4]. The role of antibodies is less clear, as they are
frequently present before and at onset of PML [5]. Currently,
there is no speciﬁc antiviral or other drug to treat PML, and
the only option is to restore protective immunity. The hemato-
poietic growth factor interleukin 7 (IL-7) is crucial for homeo-
static T-cell proliferation [6] and restores T-cell function,
including virus-speciﬁc immunity [7]. Because vaccines induce
antigen-speciﬁc immune responses, we reasoned that a thera-
peutic vaccine against JCV along with IL-7 treatment for gene-
ral immune restoration might be effective by preferentially
expanding JCV-speciﬁc CD4+ T-cells over other speciﬁcities.
We have treated 2 PML patients, who suffered from hereditary
or acquired immunocompromise, with 3 subcutaneous injec-
tions of recombinant human IL-7 (rhIL-7 [CYT107]) and a
therapeutic vaccine consisting of JCV VP1 protein in combina-
tion with a topically administered Toll-like receptor 7 (TLR7)
agonist as adjuvant [8], and report the results herein.
METHODS
Ethics Statement
Both patients received the above-mentioned treatment as
“Compassionate Use,” which refers to use of a nonapproved
drug or biological/chemical compound outside the framework
of a clinical trial. The physician acts here in the scope of her/his
medical license and takes complete responsibility for the pre-
scribed therapy. When using a nonapproved medication, the
patient must be adequately informed and special authorization
at the local Agency for Therapeutic Products obtained. Both pa-
tients were treated in full compliance with regulatory require-
ments in Germany and Switzerland. Patients and relatives
were informed of the risks of the treatment, including death
from PML immune reconstitution inﬂammatory syndrome
(IRIS), and signed an informed consent.
Patients
Clinical information and neuroimaging (magnetic resonance
imaging [MRI]), virological, and immunological ﬁndings are
summarized in Supplementary Table 1. Both patients signiﬁ-
cantly deteriorated during the 12 months between diagnosis
and treatment, and cerebrospinal ﬂuid (CSF) JCV DNA re-
mained positive during this time. Both patients were uninfected
with human immunodeﬁciency virus (HIV).
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Figure 1. Treatment protocol (upper scheme). Dotted gray lines represent time points of recombinant human interleukin 7 (rhIL-7) injection (patient 1: days
–2 and 5; patient 2: days –2 and 7), solid gray lines represent time points of VP1 injection in combination with imiquimod (patient 1: days 0 and 41; patient 2:
days 0 and 43), and black solid line represents simultaneous injection of VP1 and rhIL-7 in combination with imiquimod (patient 1: day 12; patient 2: day 17).
Day 0 is the day of the ﬁrst VP1 injection. Subtle differences in schedule between the 2 patients were due to an intercurrent urinary tract infection in patient
2. A, JC polyomavirus (JCV) load in cerebrospinal ﬂuid from patient 1 (left) and patient 2 (right), before and at different time points during and after treat-
ment. The y-axis represents viral load expressed as viral genome copies/mL and the x-axis shows time in days. B, T2 magnetic resonance imaging (MRI)
from patient 1 (left top row) and patient 2 (right top row) before treatment and 12 or 14 months after treatment. Contrast-enhanced T1W MRI in patient 1
(left bottom row) and in patient 2 (right bottom row) performed before and 40 days (patient 1) or 17 days (patient 2) after ﬁrst VP1 injection. White arrows
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Treatment Regimen and Follow-up
Patients were treated with 3 subcutaneous injections of glycosy-
lated rhIL-7, 10 µg/kg body weight (CYT107, Cytheris S.A., Paris,
France), 3 subcutaneous injections of 1 mg of recombinant JCV
VP1 protein (Life Science Inkubator, Bonn, Germany), and top-
ical imiquimod cream at the subcutaneous injection site (5%, Al-
dara, MEDA Pharm, Germany); a TLR7/8 agonist was used as
adjuvant [8]. The treatment protocol is summarized in Figure 1.
Tolerability and safety were assessed by clinical and labora-
tory adverse events (AEs) (Institute of Clinical Chemistry, Uni-
versity Medical Center Hamburg-Eppendorf, and the Institute
of Clinical Chemistry, Hematology, and Neurology Clinics,
University Hospital Zurich). Efﬁcacy assessment included
JCV DNA load, MRI, clinical observation, and immunological
testing. Cranial MRI examinations (T1 pre- and postgadolinium,
proton density/T2, ﬂuid-attenuated inversion recovery, and
diffusion-weighted images) were performed at the Department
of Neuroradiology, University Medical Center Hamburg-
Eppendorf, and the Institute for Neuroradiology, University
Hospital Zurich. The Scripps neurological rating scale (SNRS)
was used to assess the clinical status (100 = normal to 0 = dead).
Quantiﬁcation of JCV Viral Load
Viral load was quantiﬁed in the CSF by quantitative polymerase
chain reaction of JCV T antigen as previously described [9].
Proliferative Assays
Proliferative response of peripheral blood mononuclear cells
(PBMCs) against VP1 (2 µg/mL [10]) and tetanus toxoid (TT,
10 µg/mL; Novartis Behring, Marburg, Germany) was tested in
a 7-day 3H-thymidine incorporation assay, and stimulatory in-
dices were calculated as follows: [mean counts per minute with
protein / mean counts per minute unstimulated wells]. Prolifer-
ation was also determined by ﬂow cytometry using CellTrace
carboxyﬂuorescein succinimidyl ester (CFSE) kit (Invitrogen,
Darmstadt, Germany) in PBMCs seeded with VP1 protein
(2 µg/mL) for 6 days, labeled with CFSE, and restimulated or
not with VP1. After 5 days, cells were stained with anti-CD4
(Biolegend, San Diego, California), anti-CD3 (eBioscience,
San Diego, California), anti-CD25 (Biolegend), and anti-
CD45RO (Biolegend). Samples were acquired using LSR-II
and LSR-Fortessa ﬂow cytometers (BD, Franklin Lakes, New
Jersey) and data analyzed using FACSDiva Software (BD).
ELISA for VP1-Speciﬁc Antibodies
VP1-speciﬁc immunoglobulin G titers in CSF/serum were
determined as previously described [11]. Samples were pread-
sorbed with soluble BK virus VP1 to compete potentially
cross-reactive antibodies. Virus-speciﬁc antibody indices (AI)
were calculated as previously described [12]. AI values ≥1.5 in-
dicate intrathecal antigen-speciﬁc antibody synthesis.
Statistical Analysis
Statistical analyses were performed with Prism 5.02 (GraphPad
Software Inc, San Diego, California). Descriptive statistics are
reported as mean ± SEM. Comparisons of ≥3 groups were as-
sessed by 1-way analysis of variance with Bonferroni correction




Only patient 1 reported a mild AE (swelling and reddening at
the rhIL-7 injection site). No hematological or blood chemistry
abnormalities were observed, and all compounds were tolerated
well.
Efﬁcacy
A clear reduction in the CSF JCV load was observed in both pa-
tients (Figure 1A). JCV viral load testing remained negative dur-
ing follow-up (12 months). Regarding MRI, no new T2 lesions
were observed after treatment (Figure 1B). Contrast-enhancing
lesions never occurred in either patient before treatment over a
12-month period. After treatment, we observed a subtle gado-
linium-enhancing MRI lesion in patient 1, and clear enhance-
ment in patient 2 indicative of an immune response in PML
lesions (Figure 1B). Clinically, stabilization and/or amelioration
of neurological ﬁndings after treatment was observed in both
patients (see SNRS scores in Figure 1C). Patient 1 signiﬁcantly
deteriorated during the 12 months between diagnosis and treat-
ment (SNRS score dropped from 78 to 71). At the time of treat-
ment, he showed bilateral cerebellar signs of the lower limbs
with gait ataxia and severe aphasia with leading comprehension
deﬁcits. Following treatment, he stabilized and perceptibly im-
proved regarding cerebellar signs, speech, and cognitive func-
tions while remaining stable during follow-up (SNRS score
Figure 1 continued. point at gadolinium contrast enhancement indicative of neuroinﬂammation in the areas of progressive multifocal leukoencephalopathic
lesions in both patients. The inset in the image of patient 1 focuses on the bandlike gadolinium-contrast-enhancing lesion. C, Scripps neurological rating
scale before treatment and 3 months and 12 or 14 months after treatment. D, JCV VP1–speciﬁc and tetanus toxoid–speciﬁc CD4+ T-cell responses before
(month –1, white histograms), during (patient 1: days 12 and 41; patient 2: days 17 and 43; gray histograms), and after (day 84, black histograms) rhIL-7/JCV
VP1 vaccination treatment. Proliferative responses were measured by 3H-thymidine incorporation assay. Mean ± SEM and statistical signiﬁcance are shown.
*P < .05, **P < .01, ***P < .001. Abbreviations: CSF, cerebrospinal ﬂuid; GC, genome copies; IL-7, interleukin 7; JCPyV, JC polyomavirus; NA, not available;
SI, stimulation index; SNRS, Scripps neurological rating scale; TT, tetanus toxoid.
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80). Patient 2, who had steadily deteriorated before treatment,
developing left-sided hemiplegia and becoming largely bedrid-
den (SNRS score 49), stabilized clinically after treatment with
signs of mild neuropsychological improvement regarding alert-
ness (SNRS score 53). Finally, JCV VP1–speciﬁc CD4+ T-cell
responses served as a mechanistic efﬁcacy measure. Before treat-
ment, PBMCs of both patients failed to respond to VP1 pro-
tein despite JCV infection. After treatment, proliferation of
VP1-speciﬁc CD4+ T-cells rose signiﬁcantly in both patients
(Figure 1D). CFSE-labeled PBMCs from patient 1 after treat-
ment and stimulated in vitro with VP1 conﬁrmed that prolifer-
ating cells were mainly memory CD4+ T-cells, although CD8+
T-cell proliferation also rose (Supplementary Figure 1A). T-cell
responses to the recall antigen TT were normal before treatment
in patient 1 and remained unchanged at the end of treatment. In
patient 2, TT-speciﬁc CD4+ T-cell responses were negative but
turned positive after treatment, most likely as an effect of
immune reconstitution by rhIL-7 (Figure 1D). Supporting this
notion, the abnormally low CD4/CD8 ratio in both patients
increased to normal levels after treatment (Supplementary
Figure 1B). Intrathecal VP1-speciﬁc antibody responses were
elevated before treatment in both patients and did not change
after treatment (Supplementary Figure 1C).
DISCUSSION
PML is often fatal in immunocompromised patients, and there
is currently no treatment. Only immune reconstitution with
rhIL-7 (CYT107) represents an option based on preliminary
data. Here, we performed 2 individual treatment attempts fol-
lowing ethical guidelines in 2 patients with PML, who suffered
from hereditary or acquired CD4 lymphopenia. Although these
2 patients could be seen as not sufﬁciently representative as they
showed a longer survival than the majority of untreated PML
patients, they signiﬁcantly deteriorated during the 12 months
between diagnosis and treatment. Due to the often fatal out-
come of PML, they were treated with subcutaneous injections
of rhIL-7 (CYT107) with the aim to restore overall immune
function. We have previously shown that JCV VP1–speciﬁc
CD4+ T-cells are highly enriched in the brain during PML-IRIS
and are probably critical for eliminating JCV from the central
nervous system [3]. Because restoration of immune competence
may not be sufﬁcient to expand these JCV VP1–speciﬁc CD4+
T-cells even in the presence of JCV and VP1 in the brain, we
decided to also vaccinate patients with JCV VP1 protein via an
immunogenic route, that is, subcutaneously, in combination
with a TLR7 agonist as adjuvant to assure boosting of VP1-
speciﬁc CD4+ T-cell responses over other speciﬁcities. This
PML treatment was not only well tolerated, but most impor-
tantly also appears to have long-lasting efﬁcacy with respect
to elimination of CSF JCV viral load, induction of MRI-proven
inﬂammation at sites of PML lesions without prominent/classi-
cal PML-IRIS, and clinical stabilization with slight improve-
ment. This efﬁcacy means that the 2 aims of our treatment, to
restore overall immune responsiveness and to boost JCV VP1–
speciﬁc CD4+ T-cells, were accomplished. Immune restoration
by rhIL-7 was evident in patient 2, who had a low response to
the recall antigen TT and who regained responsiveness after
treatment. Along this line, the peripheral CD4/CD8 ratio was
also normalized after treatment in both patients. Furthermore,
CD4+ JCV VP1–speciﬁc T-cell responses increased signiﬁcantly,
from previously negative in both patients. Despite these encour-
aging results, additional investigation of treatment efﬁcacy in
PML patients with more severe immunocompromise is warranted
to discern the relative contribution of each compound and the pu-
tative role of VP1-speciﬁc CD8+ T-cells. Furthermore, although
this therapeutic approach is not suitable for patients with HIV
or with monoclonal antibody treatment–associated PML, in
whom immune reconstitution is not the limiting factor, we be-
lieve that HIV patients or patients who will start on or are al-
ready treated with therapies that pose the risk of PML might
beneﬁt from a prophylactic vaccination with VP1.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data
provided by the author that are published to beneﬁt the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
Notes
Acknowledgments. We thank Björn Zörner and Nikolai Pfender for
assistance in clinical management, Brenda Reinhart for carefully reading
the manuscript, and Magdalena Foege for preparation of regulatory docu-
ments, all at Neuroimmunology and Multiple Sclerosis Research, Depart-
ment of Neurology, University of Zurich.
Financial support. The Institute for Neuroimmunology and Clinical
Multiple Sclerosis Research was supported by the Gemeinnützige Hertie
Stiftung. The Section of Neuroimmunology and Multiple Sclerosis Research
is supported by the Clinical Research Priority Program onMultiple Sclerosis
of the University of Zurich.
Potential conﬂicts of interest. T. C. is an employee of Cytheris, which
produces rhIL-7 (CYT107). M. S., S. Y., I. J., S. S., and R. M. are coinventors
of a patent application held by the University of Zurich. All other authors
report no potential conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and
other disorders caused by JC virus: clinical features and pathogenesis.
Lancet Neurol 2010; 9:425–37.
2. Cinque P, Pierotti C, Vigano MG, et al. The good and evil of HAART in
HIV-related progressive multifocal leukoencephalopathy. J Neurovirol
2001; 7:358–63.
BRIEF REPORT • CID 2014:59 (1 December) • 1591
3. Aly L, Yousef S, Schippling S, et al. Central role of JC virus-speciﬁc
CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-
immune reconstitution inﬂammatory syndrome. Brain 2011; 134(pt 9):
2687–702.
4. Gheuens S, Bord E, Kesari S, et al. Role of CD4+ and CD8+ T-cell
responses against JC virus in the outcome of patients with pro-
gressive multifocal leukoencephalopathy (PML) and PML with
immune reconstitution inﬂammatory syndrome. J Virol 2011; 85:
7256–63.
5. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implica-
tions for PML risk stratiﬁcation. Ann Neurol 2010; 68:295–303.
6. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for ther-
apeutic application. Nat Rev Immunol 2011; 5:330–42.
7. Pellegrini M, Calzascia T, Toe JG, et al. IL-7 engages multiple mecha-
nisms to overcome chronic viral infection and limit organ pathology.
Cell 2011; 144:601–13.
8. Feyeraband S, Stevanovic S, Gouttefangeas C, et al. Novel multi-peptide
vaccination in HLA-A2+ hormone sensitive patients with biochemical
relapse of prostate cancer. Prostate 2009; 69:917–27.
9. Pal A, Sirota L, Maudru T, Peden K, Lewis AM. Real-time quantitative
PCR assays for the detection of virus-speciﬁc DNA in samples with
mixed populations of polyomaviruses. J Virol Methods 2006; 135:32–42.
10. Goldmann C, Petry H, Frye S, et al. Molecular cloning and expression of
major structural protein VP1 of the human polyomavirus JC virus: for-
mation of virus-like particles useful for immunological and therapeutic
studies. J Virol 1999; 73:4465–9.
11. Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal
humoral immune response in progressive multifocal leukoencephalop-
athy. J Infect Dis 1997; 176:250–4.
12. Reiber H, Lange P. Quantiﬁcation of virus-speciﬁc antibodies in cere-
brospinal ﬂuid and serum: sensitive and speciﬁc detection of antibody
synthesis in brain. Clin Chem 1991; 37:1153–60.
1592 • CID 2014:59 (1 December) • BRIEF REPORT
